Skip to main content
Journal cover image

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial.

Publication ,  Journal Article
Nair, S; Diehl, AM; Wiseman, M; Farr, GH; Perrillo, RP
Published in: Aliment Pharmacol Ther
July 1, 2004

BACKGROUND: Insulin sensitizing agents may be useful in treatment of non-alcoholic fatty liver disease. AIM: A pilot study to evaluate the efficacy and safety of metformin in non-alcoholic fatty liver disease. METHODS: In an open labelled study, patients with histologically confirmed non-alcoholic fatty liver disease were given metformin (20 mg/kg) for 1 year. Insulin resistance (by log homeostasis assessment model analysis for insulin resistance and Quantitative Insulin Sensitivity Check Index) and post-treatment hepatic histology were compared with pre-treatment histology. RESULTS: Fifteen patients completed 1 year of treatment. During the initial 3 months, there was improvement in alanine aminotransferase and aspartate aminotransferase (P-value 0.01 and 0.02, respectively) along with improvement in insulin sensitivity. However, after 3 months, there was no further improvement in insulin sensitivity and there was gradual rise in aspartate aminotransferase and alanine aminotransferase back to pre-treatment levels. Among the 10 patients with post-treatment biopsy, three (33%), showed improvement in steatosis, two (20%) showed improvement in inflammation score and one (10%) showed improvement in fibrosis. CONCLUSION: Metformin treatment was associated with only a transient improvement in liver chemistries. A progressive, sustainable reduction in insulin sensitivity was not noted during treatment.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Aliment Pharmacol Ther

DOI

ISSN

0269-2813

Publication Date

July 1, 2004

Volume

20

Issue

1

Start / End Page

23 / 28

Location

England

Related Subject Headings

  • Treatment Outcome
  • Pilot Projects
  • Patient Compliance
  • Middle Aged
  • Metformin
  • Male
  • Insulin Resistance
  • Hypoglycemic Agents
  • Humans
  • Hepatitis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Nair, S., Diehl, A. M., Wiseman, M., Farr, G. H., & Perrillo, R. P. (2004). Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther, 20(1), 23–28. https://doi.org/10.1111/j.1365-2036.2004.02025.x
Nair, S., A. M. Diehl, M. Wiseman, G. H. Farr, and R. P. Perrillo. “Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial.Aliment Pharmacol Ther 20, no. 1 (July 1, 2004): 23–28. https://doi.org/10.1111/j.1365-2036.2004.02025.x.
Nair S, Diehl AM, Wiseman M, Farr GH, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther. 2004 Jul 1;20(1):23–8.
Nair, S., et al. “Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial.Aliment Pharmacol Ther, vol. 20, no. 1, July 2004, pp. 23–28. Pubmed, doi:10.1111/j.1365-2036.2004.02025.x.
Nair S, Diehl AM, Wiseman M, Farr GH, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther. 2004 Jul 1;20(1):23–28.
Journal cover image

Published In

Aliment Pharmacol Ther

DOI

ISSN

0269-2813

Publication Date

July 1, 2004

Volume

20

Issue

1

Start / End Page

23 / 28

Location

England

Related Subject Headings

  • Treatment Outcome
  • Pilot Projects
  • Patient Compliance
  • Middle Aged
  • Metformin
  • Male
  • Insulin Resistance
  • Hypoglycemic Agents
  • Humans
  • Hepatitis